Traditionally, inflammatory bowel disease (IBD) has been considered a disease of the Western world. Recent studies have shown a rapid increase in incidence in emerging markets in the Middle East, Asia, and South America whereas incidence rates in the Western world have remained relatively constant in the 21st century.
Globally, the number of inflammatory bowel disease cases has increased from 3.32 million in 1990 to 4.90 million cases in 2019, an increase of 47.45%.1
Many aspects of IBS are currently not comprehensively understood; the underlying pathophysiology of the disease seems to be related to genetic factors, intestinal microbiota, and other environmental factors such as diet, smoking, or physiological stress.
The multiple and persistent symptoms of IBS contribute to a compromised quality of life, frequent absenteeism, and a high socioeconomic burden.
There is no single test to confirm the presence of irritable bowel disease. Diagnosis is based on a combination of blood tests to rule out the disease but as well on stool tests, e.g. calprotectin and total bile acids, which represent a non-invasive and inexpensive method in the assessment of IBD.
To replace technically complex and time-consuming methods to diagnose inflammatory bowel disease, DiaSys offers a clinical chemistry test to determine total bile acids in stool.
Total bile acids 21 FS is liquid-stable, ready to use, and can be used on almost all clinical chemistry analyzers. The test is characterized by a powerful performance, repeatable results and stands out for delivering results within a short time.
The dedicated calibrator TruCal TBA - initially introduced for serum application - and TruLab N and P, the multiparameter controls in the normal and pathological range, are as well suitable for stool diagnostics.
1. Wang R, Li Z, Liu S, et al Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systemic analysis based on the Global Burden of Disease Study 2019 BMJ Open 2023; 13:e065186. doi: 10.1136/bmjopen-2022-065186.